Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey; Sue Ann Costa Clemens; Shabir A. Madhi; Lily Yin Weckx; Pedro M. Folegatti; Parvinder K. Aley; Brian Angus; Vicky L. Baillie; Shaun Barnabas; Qasim Bhorat; Sagida Bibi; Carmen Briner; Paola Cicconi; Andrea M. Collins; Rachel Colin-Jones; Clare Cutland; Thomas C. Darton; Keertan Dheda; C.J. Duncan; Katherine R. W. Emary; Katie Ewer; Lee Fairlie; Saul N. Faust; Shuo Feng; Daniela M. Ferreira; Adam Finn; Anna L. Goodman; Catherine Green; Christopher Green; Paul T. Heath; Catherine Hill; Helen Hill; Ian Hirsch; Susanne H. Hodgson; Alane Izu; Susan Jackson; Daniel Jenkin; Carina C. D. Joe; Simon Kerridge; Anthonet Koen; Gaurav Kwatra; Rajeka Lazarus; Alison M. Lawrie; Alice Lelliott; Vincenzo Libri; Patrick Lillie; Raburn M. Mallory; Ana Verena Almeida Mendes; Eveline Pı́polo Milan; Angela M. Minassian; Alastair McGregor; Hazel Morrison; Yama F Mujadidi; Anusha Nana; Peter O’Reilly; Sherman D. Padayachee; Ana Maria Pittella; Emma Plested; Katrina M. Pollock; Maheshi Ramasamy; Sarah Rhead; Alexandre Vargas Schwarzbold; Nisha Singh; Darren Smith; Rinn Song; Matthew D. Snape; Eduardo Sprinz; Rebecca Sutherland; Richard Tarrant; Emma C. Thomson; M. Estée Török; Mark Toshner; David P. J. Turner; Johan Vekemans; Tonya Villafana; Marion Watson; Christopher J. Williams; Alexander D. Douglas; Adrian V. S. Hill; Teresa Lambe; Sarah C. Gilbert; Andrew J. Pollard; Marites Aban; Fatola Abayomi; Kushala W.M. Abeyskera; Jeremy Aboagye; Matthew Adam; Kirsty Adams; James P. Adamson; Yemi Adelaja; Gbadebo Adewetan; Syed Adlou; Khatija Ahmed; Yasmeen Akhalwaya; Saajida Akhalwaya; Andrew Alcock; Aabidah Ali; Elizabeth Allen; Lauren Allen; Thamires C. D. S. C Almeida

doi:10.1016/s0140-6736(20)32661-1

December 8, 2020The LancetOpen Access

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the safety and efficacy of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2.
Conducted four randomized controlled trials across Brazil, South Africa, and the UK.
Participants received the ChAdOx1 nCoV-19 vaccine or a placebo for comparison.
Interim analysis performed to assess outcomes.
Efficacy of the vaccine against symptomatic COVID-19 was demonstrated in multiple regions.
Safety profile showed acceptable rates of adverse events, aligning with prior vaccine standards.

Implication

Randomized trial assesses safety and efficacy of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2, indicating potential effectiveness.

Abstract

UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Voysey et al. (2020) studied this question.

synapsesocial.com/papers/69d9a28ec7f0c3ae80a3e287 https://doi.org/10.1016/s0140-6736(20)32661-1

View Full Paper

Ask AI

Bookmark

Share

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Key Points

Implication

Abstract

Discussion

Cite This Study

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading